Combined analysis of monocyte and lymphocyte messenger RNA expression with serum protein profiles in patients with scleroderma
Open Access
- 25 April 2008
- journal article
- systemic sclerosis
- Published by Wiley in Arthritis & Rheumatism
- Vol. 58 (5) , 1465-1474
- https://doi.org/10.1002/art.23451
Abstract
Objective: We attempted to elucidate possible pathogenetic mechanisms in scleroderma by analysis of gene expression patterns of purified monocytes and lymphocytes, as well as protein profiles of cytokines and growth factors.Methods: Expression analysis was performed on messenger RNA (mRNA) from cells that had been purified with magnetic beads. Plasma samples from the same patients were used for multiplex cytokine analysis. Potential sources of proteins were also examined by in situ hybridization of skin specimens.Results: A total of 1,800 genes from monocytes and 863 genes from CD4+ T cells were differentially expressed in scleroderma patients. As observed by other investigators using unfractionated peripheral blood cells from patients with autoimmune connective tissue diseases, the cell type–specific analyses of our scleroderma samples showed expression of genes suggesting the presence of interferon‐α (IFNα), despite the apparent absence of this cytokine in plasma. IFNα RNA was, however, expressed at enhanced levels in vascular and perivascular cells in scleroderma skin samples. While levels of interleukin‐1α (IL‐1α) and IL‐16 were among 10 proteins found to be significantly elevated in scleroderma patients, none of the large panel of plasma cytokines we analyzed correlated with the expression levels of putative IFN response genes.Conclusion: The pattern of up‐regulation of mRNA in both the monocytes and CD4 lymphocytes of scleroderma patients, together with the detection of IFNα RNA in the microvasculature, suggests that leukocytes respond to this cytokine locally in the vessels. Detection of high levels of IL‐1α and IL‐16 in plasma and the independence of these protein levels from the IFN signature, implicates an independent contribution of other cytokines to immune activation and/or inflammation in scleroderma.Keywords
This publication has 47 references indexed in Scilit:
- Rheumatoid arthritis subtypes identified by genomic profiling of peripheral blood cells: assignment of a type I interferon signature in a subpopulation of patientsAnnals of the Rheumatic Diseases, 2007
- A macrophage marker, siglec‐1, is increased on circulating monocytes in patients with systemic sclerosis and induced by type i interferons and toll‐like receptor agonistsArthritis & Rheumatism, 2007
- Signatures of differentially regulated interferon gene expression and vasculotrophism in the peripheral blood cells of systemic sclerosis patientsRheumatology, 2006
- Classification analysis of the transcriptosome of nonlesional cultured dermal fibroblasts from systemic sclerosis patients with early diseaseArthritis & Rheumatism, 2005
- Linear Models and Empirical Bayes Methods for Assessing Differential Expression in Microarray ExperimentsStatistical Applications in Genetics and Molecular Biology, 2004
- Protein interaction for an interferon-inducible systemic lupus associated gene, IFIT1Rheumatology, 2003
- Interferon and Granulopoiesis Signatures in Systemic Lupus Erythematosus BloodThe Journal of Experimental Medicine, 2003
- Markers of joint destruction: principles, problems, and potentialAnnals of the Rheumatic Diseases, 2001
- Serum tissue inhibitor of metalloproteinases in patients with systemic sclerosisJournal of the American Academy of Dermatology, 1995
- Fibrin and fibrinogen-related antigens in systemic sclerosis (scleroderma)Journal of the American Academy of Dermatology, 1991